{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T00:00:32Z","timestamp":1791849632416,"version":"4.3.4"},"reference-count":98,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","license":[{"start":{"date-parts":[[2020,10,10]],"date-time":"2020-10-10T00:00:00Z","timestamp":1602288000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hepatol. Commun."],"published-print":{"date-parts":[[2020,11]]},"abstract":"<jats:p>Patients with chronic liver disease (CLD) are becoming increasingly complex due to the rising prevalence of multimorbidity and polypharmacy. Medications are often essential to manage the underlying liver disease, complications of cirrhosis and portal hypertension, and comorbidities. However, medication\u2010related problems (MRPs) have been associated with adverse patient outcomes, including hospitalization and mortality. Factors that can contribute to MRPs in people with CLD are variable and often entwined. This narrative literature review discusses key barriers and opportunities to modify risk factors and improve medication\u2010related outcomes for people with CLD.<\/jats:p>","DOI":"10.1002\/hep4.1612","type":"journal-article","created":{"date-parts":[[2020,10,10]],"date-time":"2020-10-10T12:46:52Z","timestamp":1602334012000},"page":"1562-1577","source":"Crossref","is-referenced-by-count":32,"title":["Improving Medication\u2010Related Outcomes in Chronic Liver Disease"],"prefix":"10.1097","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6115-3420","authenticated-orcid":false,"given":"Kelly L.","family":"Hayward","sequence":"first","affiliation":[{"name":"Centre for Liver Disease Research, Faculty of Medicine,The University of Queensland, Translational Research Institute,Brisbane,QLD,Australia"},{"name":"Department of Gastroenterology and Hepatology,Princess Alexandra Hospital,Brisbane,QLD,Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6996-894X","authenticated-orcid":false,"given":"Rianne A.","family":"Weersink","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy,Deventer Hospital,Deventer,The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2020,10,10]]},"reference":[{"key":"hep41612-bib-0001-20240114","doi-asserted-by":"crossref","first-page":"7223","DOI":"10.3748\/wjg.v20.i23.7223","article-title":"Comorbidity in cirrhosis","volume":"20","year":"2014","journal-title":"World J Gastroenterol"},{"issue":"Suppl.","key":"hep41612-bib-0002-20240114","first-page":"S566","article-title":"Prevalence of comorbidities in patients with cirrhosis admitted to U.S. safety net hospitals and their impact on clinical phenotype of admission [Abstract 1007]","volume":"113","year":"2018","journal-title":"Am J Gastroenterol"},{"key":"hep41612-bib-0003-20240114","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/s40264-018-0744-1","article-title":"Prevalence of drug prescriptions and potential safety in patients with cirrhosis: a retrospective real\u2010world study","volume":"42","year":"2019","journal-title":"Drug Saf"},{"key":"hep41612-bib-0004-20240114","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1007\/s10620-013-2832-5","article-title":"Advanced disease, diuretic use, and marital status predict hospital admissions in an ambulatory cirrhosis cohort","volume":"59","year":"2014","journal-title":"Dig Dis Sci"},{"key":"hep41612-bib-0005-20240114","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/ajg.2011.314","article-title":"Hospital readmissions among patients with decompensated cirrhosis","volume":"107","year":"2012","journal-title":"Am J Gastroenterol"},{"key":"hep41612-bib-0006-20240114","doi-asserted-by":"crossref","first-page":"682","DOI":"10.14423\/SMJ.0000000000000371","article-title":"Risk factors for 30\u2010day readmissions of individuals with decompensated cirrhosis","volume":"108","year":"2015","journal-title":"South Med J"},{"key":"hep41612-bib-0007-20240114","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1002\/hep4.1334","article-title":"Medication\u2010related problems in outpatients with decompensated cirrhosis: opportunities for harm prevention","volume":"3","year":"2019","journal-title":"Hepatol Commun"},{"key":"hep41612-bib-0008-20240114","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1097\/MEG.0000000000000152","article-title":"Medication use and medical comorbidity in patients with chronic hepatitis C from a US commercial claims database: high utilization of drugs with interaction potential","volume":"26","year":"2014","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"hep41612-bib-0009-20240114","article-title":"Multimorbidity and polypharmacy in diabetic patients with NAFLD: implications for disease severity and management","volume":"96","year":"2017","journal-title":"Medicine (Baltimore)"},{"key":"hep41612-bib-0010-20240114","first-page":"533","article-title":"Opportunities and responsibilities in pharmaceutical care","volume":"47","year":"1990","journal-title":"Am J Hosp Pharm"},{"key":"hep41612-bib-0011-20240114","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1007\/s00228-019-02688-z","article-title":"Medicine use and medicine\u2010related problems in patients with liver cirrhosis: a systematic review of quantitative and qualitative studies","volume":"75","year":"2019","journal-title":"Eur J Clin Pharmacol"},{"key":"hep41612-bib-0012-20240114","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s00228-011-1105-5","article-title":"Potential drug\u2010drug interactions and adverse drug reactions in patients with liver cirrhosis","volume":"68","year":"2012","journal-title":"Eur J Clin Pharmacol"},{"key":"hep41612-bib-0013-20240114","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1007\/s00228-013-1502-z","article-title":"Dose adjustment in patients with liver cirrhosis: impact on adverse drug reactions and hospitalizations","volume":"69","year":"2013","journal-title":"Eur J Clin Pharmacol"},{"key":"hep41612-bib-0014-20240114","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1097\/MEG.0000000000001492","article-title":"Identifying characteristics of drug\u2010related problems in critically ill patients with decompensated liver cirrhosis","volume":"31","year":"2019","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"hep41612-bib-0015-20240114","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1002\/hep4.1425","article-title":"Incidence of and risk factors for hepatic encephalopathy in a population\u2010based cohort of Americans with cirrhosis","volume":"3","year":"2019","journal-title":"Hepatol Commun"},{"key":"hep41612-bib-0016-20240114","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s10620-016-4391-z","article-title":"Factors associated with medication non\u2010adherence in patients with end\u2010stage liver disease","volume":"62","year":"2017","journal-title":"Dig Dis Sci"},{"key":"hep41612-bib-0017-20240114","doi-asserted-by":"crossref","first-page":"7321","DOI":"10.3748\/wjg.v23.i40.7321","article-title":"Medication beliefs predict medication adherence in ambulatory patients with decompensated cirrhosis","volume":"23","year":"2017","journal-title":"World J Gastroenterol"},{"key":"hep41612-bib-0018-20240114","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1111\/liv.13892","article-title":"Optimizing medication management for patients with cirrhosis: evidence\u2010based strategies and their outcomes","volume":"38","year":"2018","journal-title":"Liver Int"},{"key":"hep41612-bib-0019-20240114","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1111\/jocn.13083","article-title":"Factors associated with medication adherence in patients living with cirrhosis","volume":"25","year":"2016","journal-title":"J Clin Nurs"},{"key":"hep41612-bib-0020-20240114","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1111\/jvh.12582","article-title":"Factors associated with poor adherence to antiviral treatment for hepatitis B","volume":"24","year":"2017","journal-title":"J Viral Hepat"},{"key":"hep41612-bib-0021-20240114","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/S1665-2681(19)31000-2","article-title":"Patient adherence to antiviral treatment for chronic hepatitis B and C: a systematic review","volume":"12","year":"2013","journal-title":"Ann Hepatol"},{"key":"hep41612-bib-0022-20240114","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/j.jhep.2012.07.032","article-title":"Identifying opportunities to improve management of autoimmune hepatitis: evaluation of drug adherence and psychosocial factors","volume":"57","year":"2012","journal-title":"J Hepatol"},{"key":"hep41612-bib-0023-20240114","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1111\/jan.12826","article-title":"Patients with alcohol\u2010related liver disease \u2010 beliefs about their illness and factors that influence their self\u2010management","volume":"72","year":"2016","journal-title":"J Adv Nurs"},{"key":"hep41612-bib-0024-20240114","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1007\/s10620-013-2942-0","article-title":"Consequences of perceived stigma among patients with cirrhosis","volume":"59","year":"2014","journal-title":"Dig Dis Sci"},{"key":"hep41612-bib-0025-20240114","doi-asserted-by":"crossref","first-page":"425","DOI":"10.3851\/IMP3219","article-title":"Factors associated with non\u2010adherence to HBV antiviral therapy","volume":"23","year":"2018","journal-title":"Antivir Ther"},{"key":"hep41612-bib-0026-20240114","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1038\/ajg.2012.214","article-title":"Patient knowledge about disease self\u2010management in cirrhosis","volume":"108","year":"2013","journal-title":"Am J Gastroenterol"},{"key":"hep41612-bib-0027-20240114","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1007\/s10620-006-9442-4","article-title":"Hospitalizations during the use of rifaximin versus lactulose for the treatment of hepatic encephalopathy","volume":"52","year":"2007","journal-title":"Dig Dis Sci"},{"key":"hep41612-bib-0028-20240114","first-page":"22S","article-title":"Factors affecting compliance and persistence with treatment for hepatic encephalopathy","volume":"30","year":"2010","journal-title":"Pharmacotherapy"},{"key":"hep41612-bib-0029-20240114","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1053\/j.gastro.2010.02.015","article-title":"Persistence of cognitive impairment after resolution of overt hepatic encephalopathy","volume":"138","year":"2010","journal-title":"Gastroenterology"},{"key":"hep41612-bib-0030-20240114","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1038\/ajg.2014.107","article-title":"Persistence of cognitive impairment after resolution of overt hepatic encephalopathy","volume":"109","year":"2014","journal-title":"Am J Gastroenterol"},{"key":"hep41612-bib-0031-20240114","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1097\/MEG.0b013e3283319975","article-title":"Quality of life in cirrhosis is related to potentially treatable factors","volume":"22","year":"2010","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"hep41612-bib-0032-20240114","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1080\/17425255.2020.1702022","article-title":"Safe use of medication in patients with cirrhosis: pharmacokinetic and pharmacodynamic considerations","volume":"16","year":"2020","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"hep41612-bib-0033-20240114","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/BF00566321","article-title":"Adverse drug reactions in liver cirrhosis","volume":"13","year":"1978","journal-title":"Eur J Clin Pharmacol"},{"key":"hep41612-bib-0034-20240114","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1111\/apt.12324","article-title":"Review article: prescribing medications in patients with cirrhosis \u2010 a practical guide","volume":"37","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"key":"hep41612-bib-0035-20240114","doi-asserted-by":"crossref","first-page":"3207","DOI":"10.1007\/s10620-010-1291-5","article-title":"Methotrexate in patients with primary biliary cirrhosis who respond incompletely to treatment with ursodeoxycholic acid","volume":"55","year":"2010","journal-title":"Dig Dis Sci"},{"key":"hep41612-bib-0036-20240114","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1164\/rccm.200510-1666ST","article-title":"An official ATS statement: hepatotoxicity of antituberculosis therapy","volume":"174","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"hep41612-bib-0037-20240114","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1053\/jhep.2002.30319","article-title":"Hepatotoxicity associated with nevirapine or efavirenz\u2010containing antiretroviral therapy: role of hepatitis C and B infections","volume":"35","year":"2002","journal-title":"Hepatology"},{"key":"hep41612-bib-0038-20240114","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/j.1365-2125.1991.tb05511.x","article-title":"Pharmacokinetics of metoclopramide in patients with liver cirrhosis","volume":"31","year":"1991","journal-title":"Br J Clin Pharmacol"},{"key":"hep41612-bib-0039-20240114","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1111\/bcp.13615","article-title":"Safe use of proton pump inhibitors in patients with cirrhosis","volume":"84","year":"2018","journal-title":"Br J Clin Pharmacol"},{"key":"hep41612-bib-0040-20240114","doi-asserted-by":"crossref","first-page":"879","DOI":"10.2165\/00003088-200443130-00004","article-title":"Clinical pharmacology of tramadol","volume":"43","year":"2004","journal-title":"Clin Pharmacokinet"},{"key":"hep41612-bib-0041-20240114","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.2165\/11635500-000000000-00000","article-title":"Analgesics in patients with hepatic impairment: pharmacology and clinical implications","volume":"72","year":"2012","journal-title":"Drugs"},{"key":"hep41612-bib-0042-20240114","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1002\/hep.20595","article-title":"Effects of celecoxib and naproxen on renal function in nonazotemic patients with cirrhosis and ascites","volume":"41","year":"2005","journal-title":"Hepatology"},{"key":"hep41612-bib-0043-20240114","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/0016-5085(93)91024-C","article-title":"Indomethacin\u2010induced renal dysfunction in patients with well\u2010compensated cirrhosis","volume":"104","year":"1993","journal-title":"Gastroenterology"},{"key":"hep41612-bib-0044-20240114","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1177\/00912700022008973","article-title":"Cirrhosis does not affect the pharmacokinetics and pharmacodynamics of clopidogrel","volume":"40","year":"2000","journal-title":"J Clin Pharmacol"},{"key":"hep41612-bib-0045-20240114","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/bcp.12054","article-title":"Effect of hepatic impairment on the pharmacokinetics and pharmacodynamics of a single dose of rivaroxaban, an oral, direct factor Xa inhibitor","volume":"76","year":"2013","journal-title":"Br J Clin Pharmacol"},{"key":"hep41612-bib-0046-20240114","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.thromres.2018.08.011","article-title":"Direct oral anticoagulants in patients with liver cirrhosis: a systematic review","volume":"170","year":"2018","journal-title":"Thromb Res"},{"key":"hep41612-bib-0047-20240114","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1136\/gutjnl-2019-318237","article-title":"Cirrhosis as new indication for statins","volume":"69","year":"2020","journal-title":"Gut"},{"key":"hep41612-bib-0048-20240114","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1053\/j.gastro.2016.06.055","article-title":"Altered pharmacokinetics of statins explain increased risk of rhabdomyolysis in advanced cirrhosis","volume":"151","year":"2016","journal-title":"Gastroenterology"},{"key":"hep41612-bib-0049-20240114","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/clpt.1986.134","article-title":"Nifedipine: kinetics and hemodynamic effects in patients with liver cirrhosis after intravenous and oral administration","volume":"40","year":"1986","journal-title":"Clin Pharmacol Ther"},{"key":"hep41612-bib-0050-20240114","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1046\/j.1365-2125.1996.42817.x","article-title":"Influence of liver cirrhosis on sertraline pharmacokinetics","volume":"42","year":"1996","journal-title":"Br J Clin Pharmacol"},{"key":"hep41612-bib-0051-20240114","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1055\/s-2004-832598","article-title":"Repetition of serotonin syndrome after reexposure to SSRI \u2010 a case report","volume":"37","year":"2004","journal-title":"Pharmacopsychiatry"},{"key":"hep41612-bib-0052-20240114","doi-asserted-by":"crossref","first-page":"142","DOI":"10.2165\/00003088-199529030-00002","article-title":"Clinical pharmacokinetics and pharmacodynamics of zolpidem. Therapeutic implications","volume":"29","year":"1995","journal-title":"Clin Pharmacokinet"},{"key":"hep41612-bib-0054-20240114","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s40264-017-0635-x","article-title":"Evidence\u2010based recommendations to improve the safe use of drugs in patients with liver cirrhosis","volume":"41","year":"2018","journal-title":"Drug Saf"},{"key":"hep41612-bib-0055-20240114","doi-asserted-by":"crossref","first-page":"261","DOI":"10.2165\/00002018-200831030-00007","article-title":"Use of over\u2010the\u2010counter analgesics in patients with chronic liver disease: physicians' recommendations","volume":"31","year":"2008","journal-title":"Drug Saf"},{"key":"hep41612-bib-0056-20240114","first-page":"1","article-title":"Trainees\u2019 attitudes and preferences toward the use of over the counter analgesics in patients with chronic liver disease","volume":"3","year":"2014","journal-title":"Adv Pharmacoepidemiol Drug Saf"},{"key":"hep41612-bib-0057-20240114","doi-asserted-by":"crossref","first-page":"e743","DOI":"10.3399\/bjgp18X699377","article-title":"GPs' experiences and perceptions of early detection of liver disease: a qualitative study in primary care","volume":"68","year":"2018","journal-title":"Br J Gen Pract"},{"key":"hep41612-bib-0058-20240114","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.1007\/s10620-015-3592-1","article-title":"Primary care providers report challenges to cirrhosis management and specialty care coordination","volume":"60","year":"2015","journal-title":"Dig Dis Sci"},{"key":"hep41612-bib-0059-20240114","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.3389\/fphar.2019.01031","article-title":"Evaluation of information in summaries of product characteristics (SmPCs) on the use of a medicine in patients with hepatic impairment","volume":"10","year":"2019","journal-title":"Front Pharmacol"},{"key":"hep41612-bib-0060-20240114","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1136\/dtb.2001.39425","article-title":"Failings in treatment advice, SPCs and black triangles","volume":"39","year":"2001","journal-title":"Drug Ther Bull"},{"key":"hep41612-bib-0061-20240114","doi-asserted-by":"crossref","first-page":"561","DOI":"10.2165\/00002018-200932070-00003","article-title":"Pharmacokinetic changes of psychotropic drugs in patients with liver disease: implications for dose adaptation","volume":"32","year":"2009","journal-title":"Drug Saf"},{"key":"hep41612-bib-0062-20240114","doi-asserted-by":"crossref","first-page":"399","DOI":"10.2165\/00003088-199937050-00004","article-title":"Effects of liver disease on pharmacokinetics. An update","volume":"37","year":"1999","journal-title":"Clin Pharmacokinet"},{"key":"hep41612-bib-0063-20240114","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1517\/17425255.2014.902444","article-title":"Pharmacokinetic and toxicological considerations for the treatment of diabetes in patients with liver disease","volume":"10","year":"2014","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"hep41612-bib-0065-20240114","article-title":"Evaluating the safety and dosing of drugs in patients with liver cirrhosis by literature review and expert opinion","volume":"6","year":"2016","journal-title":"BMJ Open"},{"key":"hep41612-bib-0066-20240114","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1186\/s12876-016-0530-4","article-title":"Prevalence of medication discrepancies in patients with cirrhosis: a pilot study","volume":"16","year":"2016","journal-title":"BMC Gastroenterol"},{"key":"hep41612-bib-0067-20240114","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1177\/2050640617727179","article-title":"Benzodiazepines and risk for hepatic encephalopathy in patients with cirrhosis and ascites","volume":"6","year":"2018","journal-title":"United European Gastroenterol J"},{"key":"hep41612-bib-0068-20240114","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1038\/ajg.2014.264","article-title":"Covert hepatic encephalopathy is independently associated with poor survival and increased risk of hospitalization","volume":"109","year":"2014","journal-title":"Am J Gastroenterol"},{"key":"hep41612-bib-0069-20240114","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.amjmed.2018.01.026","article-title":"Increased morbidity and mortality associated with falls among patients with cirrhosis","volume":"131","year":"2018","journal-title":"Am J Med"},{"key":"hep41612-bib-0070-20240114","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/j.cgh.2015.03.019","article-title":"Psychoactive medications increase the risk of falls and fall\u2010related injuries in hospitalized patients with cirrhosis","volume":"13","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"hep41612-bib-0071-20240114","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/j.cgh.2016.04.009","article-title":"Rates of and reasons for hospital readmissions in patients with cirrhosis: a multistate population\u2010based cohort study","volume":"14","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"key":"hep41612-bib-0072-20240114","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s00228-002-0474-1","article-title":"Multicenter hospital study on prescribing patterns for prophylaxis and treatment of complications of cirrhosis","volume":"58","year":"2002","journal-title":"Eur J Clin Pharmacol"},{"key":"hep41612-bib-0073-20240114","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1002\/hep.28737","article-title":"Proton pump inhibitors as a risk factor for hepatic encephalopathy and spontaneous bacterial peritonitis in patients with cirrhosis with ascites","volume":"64","year":"2016","journal-title":"Hepatology"},{"key":"hep41612-bib-0074-20240114","doi-asserted-by":"crossref","first-page":"4933","DOI":"10.3748\/wjg.v25.i33.4933","article-title":"Proton pump inhibitor use increases mortality and hepatic decompensation in liver cirrhosis","volume":"25","year":"2019","journal-title":"World J Gastroenterol"},{"key":"hep41612-bib-0075-20240114","doi-asserted-by":"crossref","first-page":"933","DOI":"10.5604\/01.3001.0012.7193","article-title":"Effect of proton pump inhibitors on mortality in patients with cirrhosis and spontaneous bacterial peritonitis","volume":"17","year":"2018","journal-title":"Ann Hepatol"},{"key":"hep41612-bib-0076-20240114","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1136\/gutjnl-2014-307526","article-title":"Acute kidney injury and acute\u2010on\u2010chronic liver failure classifications in prognosis assessment of patients with acute decompensation of cirrhosis","volume":"64","year":"2015","journal-title":"Gut"},{"key":"hep41612-bib-0077-20240114","first-page":"1743290","article-title":"Renal effects of angiotensin\u2010converting enzyme inhibitors and angiotensin receptor blockers in patients with liver cirrhosis: a nationwide cohort study","volume":"2019","year":"2019","journal-title":"Gastroenterol Res Pract"},{"key":"hep41612-bib-0078-20240114","doi-asserted-by":"crossref","first-page":"207","DOI":"10.14740\/jocmr2914w","article-title":"The effectiveness of a liver disease education class for providing information to patients and their families","volume":"9","year":"2017","journal-title":"J Clin Med Res"},{"key":"hep41612-bib-0079-20240114","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1097\/MEG.0000000000000579","article-title":"Patient education and its effect on self\u2010management in cirrhosis: a pilot study","volume":"28","year":"2016","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"hep41612-bib-0080-20240114","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1111\/imj.13505","article-title":"Optimising care of patients with chronic disease: patient\u2010oriented education may improve disease knowledge and self\u2010management","volume":"47","year":"2017","journal-title":"Intern Med J"},{"key":"hep41612-bib-0081-20240114","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1136\/flgastro-2016-100761","article-title":"Patient understanding of liver cirrhosis and improvement using multimedia education","volume":"8","year":"2017","journal-title":"Frontline Gastroenterol"},{"key":"hep41612-bib-0082-20240114","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/j.cgh.2013.04.024","article-title":"Education provides significant benefits to patients with hepatitis B virus or hepatitis C virus infection: a systematic review","volume":"11","year":"2013","journal-title":"Clin Gastroenterol Hepatol"},{"key":"hep41612-bib-0083-20240114","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.2147\/PPA.S224937","article-title":"A randomized controlled trial to assess the impact of clinical pharmacy interventions on treatment outcomes, health related quality of life and medication adherence among hepatitis C patients","volume":"13","year":"2019","journal-title":"Patient Prefer Adherence"},{"key":"hep41612-bib-0084-20240114","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s13584-017-0172-1","article-title":"Multi\u2010disciplinary patient\u2010centered model for the expedited provision of costly therapies in community settings: the case of new medication for hepatitis C","volume":"6","year":"2017","journal-title":"Isr J Health Policy Res"},{"key":"hep41612-bib-0085-20240114","article-title":"Improving pharmacotherapy outcomes in patients with hepatitis C virus infection treated with direct\u2010acting antivirals: the GRUviC project","volume":"71","year":"2017","journal-title":"Int J Clin Pract"},{"key":"hep41612-bib-0086-20240114","article-title":"Expanding hepatitis C virus care and cure: national experience using a clinical pharmacist\u2010driven model","volume":"6","year":"2019","journal-title":"Open Forum Infect Dis"},{"issue":"Suppl 2","key":"hep41612-bib-0087-20240114","article-title":"Gastroenterology pharmacy support team: does collaboration between medical, nursing, and pharmacy staff provide better outcomes for hepatitis C treatment? [Abstract 183]","volume":"34","year":"2019","journal-title":"J Gastroenterol Hepatol"},{"key":"hep41612-bib-0088-20240114","first-page":"304","article-title":"Implementation of a non\u2010alcoholic fatty liver disease (NAFLD) clinical pharmacy service [Abstract 356]","volume":"3","year":"2020","journal-title":"J Am Coll Clin Pharm"},{"key":"hep41612-bib-0089-20240114","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.cgh.2013.01.014","article-title":"Efficacy of a chronic disease management model for patients with chronic liver failure","volume":"11","year":"2013","journal-title":"Clin Gastroenterol Hepatol"},{"key":"hep41612-bib-0090-20240114","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1111\/liv.13494","article-title":"The patient buddy app can potentially prevent hepatic encephalopathy\u2010related readmissions","volume":"37","year":"2017","journal-title":"Liver Int"},{"issue":"Suppl. 1","key":"hep41612-bib-0091-20240114","first-page":"94","article-title":"Use of an innovative telehealth platform to reduce readmissions and enable patient\u2010centered care in cirrhotic patients [Abstract 170]","volume":"66","year":"2017","journal-title":"Hepatology"},{"key":"hep41612-bib-0092-20240114","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.dld.2017.08.024","article-title":"HEPACONTROL. A program that reduces early readmissions, mortality at 60 days, and healthcare costs in decompensated cirrhosis","volume":"50","year":"2018","journal-title":"Dig Liver Dis"},{"key":"hep41612-bib-0093-20240114","doi-asserted-by":"crossref","first-page":"301","DOI":"10.5694\/mja17.01164","article-title":"Coordinated care for patients with cirrhosis: fewer liver\u2010related emergency admissions and improved survival","volume":"209","year":"2018","journal-title":"Med J Aust"},{"key":"hep41612-bib-0094-20240114","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1111\/imj.14986","article-title":"Effectiveness of patient\u2010oriented education and medication management intervention in people with decompensated cirrhosis","volume":"50","year":"2020","journal-title":"Int Med J"},{"key":"hep41612-bib-0095-20240114","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1002\/hep.23802","article-title":"Expanding access to hepatitis C virus treatment \u2010 extension for community healthcare outcomes (ECHO) project: disruptive innovation in specialty care","volume":"52","year":"2010","journal-title":"Hepatology"},{"key":"hep41612-bib-0096-20240114","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.amjmed.2016.11.019","article-title":"Telemedicine specialty support promotes hepatitis C treatment by primary care providers in the department of Veterans Affairs","volume":"130","year":"2017","journal-title":"Am J Med"},{"key":"hep41612-bib-0097-20240114","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1093\/fampra\/cmw073","article-title":"Randomized controlled trial of an intervention to improve drug appropriateness in community\u2010dwelling polymedicated elderly people","volume":"34","year":"2017","journal-title":"Fam Pract"},{"key":"hep41612-bib-0098-20240114","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1111\/bcp.14177","article-title":"Medication safety in patients with hepatic impairment: a survey of community pharmacists' knowledge level and their practice in caring for these patients","volume":"86","year":"2020","journal-title":"Br J Clin Pharmacol"},{"key":"hep41612-bib-0099-20240114","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.jamda.2018.10.026","article-title":"Health outcomes of deprescribing interventions among older residents in nursing homes: a systematic review and meta\u2010analysis","volume":"20","year":"2019","journal-title":"J Am Med Dir Assoc"},{"key":"hep41612-bib-0100-20240114","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1111\/bcp.14113","article-title":"Outcomes of deprescribing interventions in older patients with life\u2010limiting illness and limited life expectancy: a systematic review","volume":"86","year":"2020","journal-title":"Br J Clin Pharmacol"}],"container-title":["Hepatology Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hep4.1612","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/hep4.1612","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/10.1002\/hep4.1612","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,14]],"date-time":"2024-01-14T11:10:53Z","timestamp":1705230653000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1002\/hep4.1612"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,10]]},"references-count":98,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1002\/hep4.1612","relation":{},"ISSN":["2471-254X","2471-254X"],"issn-type":[{"value":"2471-254X","type":"print"},{"value":"2471-254X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,10]]}}}